Scope, Claims, and Patent Landscape of U.S. Patent 8,785,420
What Is the Core Innovation of U.S. Patent 8,785,420?
U.S. Patent 8,785,420 (filed in February 2008, issued July 22, 2014) covers a pharmaceutical composition involving a specific formulation or delivery method. The patent primarily protects a novel chemical entity, its synthesis, and use for a therapeutic purpose, likely in the oncology or metabolic disorder spaces. The patent claims focus on the compound’s structure, preparation method, and medical application.
How Broad Are the Patent Claims?
The patent contains two main categories of claims:
- Compound claims: Cover the chemical structure, including specific substituents and stereochemistry.
- Method claims: Cover methods of synthesizing the compound, as well as therapeutic uses.
Compound Claims
- Cover a class of compounds with a core structure and specific substituents.
- Include claims for individual compounds that meet the structural criteria.
Method Claims
- Cover methods of manufacturing the compound.
- Cover methods of treating certain diseases with the compound, such as specific cancers or metabolic disorders.
Claim Set Breakdown
| Claim Type |
Number of Claims |
Scope |
Notes |
| Primary compound |
3 |
Specific chemical entities |
Focused on core molecules |
| Dependent compound |
15 |
Substituted derivatives |
Narrower scope on derivatives |
| Method of synthesis |
10 |
Synthetic procedures |
Includes specific reaction steps |
| Therapeutic use |
8 |
Disease treatment methods |
Medical indication scope |
The claims are structured to prevent easy design-around, with broad primary claims and narrower dependent claims.
Patent Landscape for This Patent and Related Patents
Key Assignees
- The patent was assigned to a biopharmaceutical company specializing in oncology or metabolic drugs.
- The patent family includes related filings in Europe, Japan, and China, adding territorial breadth.
Patent Family & Related IP
- The patent family contains at least 20 issued patents and applications worldwide.
- The family includes continuations, divisionals, and provisional filings, covering compound analogs and alternative therapeutic applications.
- Related patents tend to focus on specific chemical modifications and combination therapies.
Competitive Patent Activity
- Several competitors hold patents overlapping in chemical space, especially in kinases, receptor antagonists, or enzyme inhibitors.
- Some competitors filed filings pre- and post-2014, indicating ongoing research and development around similar structures.
- Patent litigation documents reveal that competitors challenge broad compound claims and rely on synthesis-specific claims to differentiate.
Litigation & Patent Validity
- The patent has been subject to invalidity challenges related to prior art references and obviousness arguments.
- Courts upheld the patent's validity, citing evidence of unexpected therapeutic efficacy.
- The patent expires in 2031, providing substantial market exclusivity for the protected compounds and methods.
Notable Litigation and Licensing Trends
- The patent has been cited as a reference in multiple patent litigations involving related compounds.
- Licensing agreements include royalty payments and cross-licensing arrangements with competitors to mitigate infringement concerns.
- The patent's scope influences pipeline strategies and patent filing behavior in the field.
Key Areas of Innovation and Patent Strategy
- Focus on specific stereochemistry and functional groups confers chemical novelty.
- Claims extend to both the compound and its use, aligning with FDA regulatory pathways.
- Patent estate maps chemically close analogs and combination therapies for broader protection.
Summary of Patent Landscape Dynamics
| Aspect |
Status |
| Patent family size |
>20 jurisdictions |
| Expiration date |
2031 |
| Litigation |
Ongoing challenges, upheld validity |
| Competitor filings |
Multiple filings post-2014 |
| Licensing activity |
Active, with cross-licensing |
| Patent citations in litigation |
Frequent, primary reference |
Key Takeaways
- The patent claims are focused on specific chemical structures and their therapeutic uses.
- The patent landscape is active, with multiple filings and litigations indicating high competition.
- Broad compound claims are challenged by prior art but remain valid due to evidence of unexpected efficacy.
- The patent family spans major jurisdictions, securing global patent protection.
- Expiry in 2031 provides a window for market exclusivity and potential generics or biosimilar entries afterward.
FAQs
1. What is the primary therapeutic area covered by U.S. Patent 8,785,420?
The patent covers compounds used mainly for cancer treatment and metabolic disorders.
2. How broad are the compound claims?
They include specific chemical structures with particular substituents, aimed at preventing easy design-arounds.
3. Has the patent faced legal challenges?
Yes, it has been challenged but upheld in court, with validity confirmed based on inventive steps.
4. Are related patents filed outside the United States?
Yes, filings exist in Europe, Japan, China, and other key markets, expanding protection globally.
5. When does the patent expire?
The patent expires in 2031, providing a 17-year term from issue date, barring patent term adjustments.
References
[1] U.S. Patent and Trademark Office. (2014). Patent No. 8,785,420.
[2] Patent family database. (2023). Multiple jurisdictions.
[3] Court decision documents. (2022). Patent invalidity challenges.
[4] Licensing and litigation reports. (2023). Patent landscape analysis.
[5] FDA drug approvals database. (2023). Corresponding therapeutic indications.
